XNYS
BDX
Market cap54bUSD
Jul 09, Last price
150.85USD
1D
0.19%
1Q
-2.19%
Jan 2017
18.80%
Name
Becton Dickinson and Co
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Becton, Dickinson and Company (BD) is a global medical technology enterprise engaged in the development, manufacture, and distribution of a comprehensive range of medical supplies, advanced devices, laboratory equipment, and diagnostic products. Its vast product portfolio caters to healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public worldwide. The company operates through distinct segments. The BD Medical segment supplies a wide array of products including various peripheral and central intravenous (IV) catheters, vascular care and preparation solutions, needle-free IV connectors, and closed-system drug transfer devices. It also provides hypodermic, anesthesia, and enteral syringes and needles, sharps disposal systems, and prefillable drug delivery solutions. Additionally, this segment offers comprehensive medication management systems, covering IV medication and infusion therapy delivery, compounding workflow, automated dispensing, supply management, and inventory optimization, alongside syringes and pen needles specifically for diabetes care. The BD Life Sciences segment offers diagnostic and research tools, including specimen and blood collection products. Its offerings span automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology, in addition to rapid diagnostic assays, microbiology laboratory automation products, and plated media. For cell analysis, it provides fluorescence-activated cell sorters and analyzers, antibodies, kits, reagent systems, and solutions for single-cell gene expression, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. BD Interventional focuses on surgical and interventional solutions, featuring products for hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and various other surgical applications. This segment also includes items for surgical infection prevention, surgical and laparoscopic instrumentation, peripheral intervention, and specialized urology and critical care products. Founded in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑09 | 2024‑09 | 2023‑09 | 2022‑09 | 2021‑09 | 2020‑09 | 2019‑09 | 2018‑09 | 2017‑09 | 2016‑09 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||